Sigilon Therapeutics
2 followers
Sigilon Therapeutics’ mission is to create immune-protected, engineered human cells that restore normal physiology in a wide range of diseases without generating fibrosis or immune rejection, liberating patients from challenges associated with serious chronic diseases.
Org chart
Rogerio Vivaldi
President & CEO
Rogerio Vivaldi
Collapse
Sarah Yuan
Chief Technical Operations Officer
Philip Ashton-Rickardt
Chief Scientific Officer
Jiang Wu
VP & Head, Bioanalytical & CMC Analytical Development
Olivia G. Kelly
VP, Head, Islet Cell Therapy Research
Joseph Tumang
VP & Head, Immune Mediated Diseases
Jamie Murphy
VP, Finance & Controller
Omid Veiseh
Co-founder
Marylou Ross
Senior Associate Engineer - Process Development
Jillian Higgins
Principle Associate Scientist
Eric Shaff
Corporate Director
Michael Owings
Head Of Quality
Teams
View all
